Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
728 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT01843725 | Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers(MOMENTUM1) | completed | Phase 1 | 37 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02316028 | Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)(DECIT) | completed | Phase 1 / Phase 2 | 11 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT01851265 | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | completed | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 2, 2017 | clinicaltrials |
| NCT02155582 | Copanlisib Pharmacodynamic Study | completed | Phase 1 | 63 | BayerINDUSTRY | 3 | Jun 16, 2017 | clinicaltrials |
| NCT00148928 | Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT00058526 | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | completed | Phase 1 | 61 | GlaxoSmithKlineINDUSTRY | 5 | May 15, 2017 | clinicaltrials |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | terminated | Phase 1 | 71 | GlaxoSmithKlineINDUSTRY | 6 | May 15, 2017 | clinicaltrials |
| NCT00478621 | Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A) | completed | Phase 1 | 540 | GlaxoSmithKlineINDUSTRY | 1 | May 10, 2017 | clinicaltrials |
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | completed | Phase 1 | 24 | argenxINDUSTRY | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01420146 | Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients(IJBMNZrT003) | completed | Phase 1 | 20 | Jules Bordet InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT01929603 | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Jan 16, 2017 | clinicaltrials |
| NCT02334709 | Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. | completed | Phase 1 / Phase 2 | 13 | University Hospital, GhentOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02406183 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | completed | Phase 1 | 13 | RadiotherapieOTHER | 1 | Jan 10, 2017 | clinicaltrials |
| NCT02081495 | A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | completed | Phase 1 | 35 | Janssen Research & Development, LLCINDUSTRY | 4 | Nov 11, 2016 | clinicaltrials |
| NCT01148758 | A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01254526 | Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 52 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01849666 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01085331 | MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 / Phase 2 | 16 | EMD SeronoINDUSTRY | 3 | Oct 19, 2016 | clinicaltrials |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 5 | Oct 13, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT00507091 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 25, 2016 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT00450892 | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | completed | Phase 1 / Phase 2 | 129 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 7, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | completed | Phase 1 | 20 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | May 11, 2016 | clinicaltrials |
| NCT00876044 | A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients(QUTIE) | completed | Phase 1 | 88 | SanofiINDUSTRY | 7 | May 5, 2016 | clinicaltrials |
| NCT01943838 | A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT01273493 | A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction | completed | Phase 1 | 15 | Janssen Research & Development, LLCINDUSTRY | 4 | Feb 15, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials